Cardiovascular Systems, Inc. (CSII): Price and Financial Metrics
Cardiovascular Systems, Inc. (CSII)
Today's Latest Price: $39.34 USD
Updated Jun 3 2:15pm
Add CSII to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 132 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
CSII Stock Summary
- The price/operating cash flow metric for Cardiovascular Systems Inc is higher than 99.23% of stocks in our set with a positive cash flow.
- The ratio of debt to operating expenses for Cardiovascular Systems Inc is higher than it is for about just 12.13% of US stocks.
- Over the past twelve months, CSII has reported earnings growth of -319.61%, putting it ahead of only 5.34% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to Cardiovascular Systems Inc, a group of peers worth examining would be CSPI, ASPN, FEIM, AMRN, and RELL.
- CSII's SEC filings can be seen here. And to visit Cardiovascular Systems Inc's official web site, go to www.csi360.com.
CSII Stock Price Chart More Charts
CSII Price/Volume Stats
| Current price | $39.34 | 52-week high | $55.22 |
| Prev. close | $38.02 | 52-week low | $26.00 |
| Day low | $37.80 | Volume | 91,730 |
| Day high | $39.38 | Avg. volume | 310,986 |
| 50-day MA | $38.13 | Dividend yield | N/A |
| 200-day MA | $43.51 | Market Cap | 1.39B |
Cardiovascular Systems, Inc. (CSII) Company Bio
Cardiovascular Systems develops, manufactures, and markets devices for the treatment of vascular diseases, targeting a range of plaque types in leg arteries above and below the knee. The company was founded in 1989 and is based in St. Paul, Minnesota.
CSII Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $39.34 | $0.03 | -100% |
Below please find a table outlining a discounted cash flow forecast for CSII, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cardiovascular Systems Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for CSII, they are:
- The company's compound free cash flow growth rate over the past 3.26 years comes in at -0.38%; that's greater than only 3.37% of US stocks we're applying DCF forecasting to.
- The company has produced more trailing twelve month cash flow than only 4.92% of its sector Healthcare.
- The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 6.85% of the free cash flow producing stocks we're observing.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -100% |
| 1% | -100% |
| 2% | -100% |
| 3% | -100% |
| 4% | -100% |
| 5% | -100% |
AGHC, ALC, ANGO, ELAN, and HAPP can be thought of as valuation peers to CSII, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...